Mirum CFO sells 6,001 shares under trading plan

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc.'s Chief Financial Officer, Eric Bjerkholt, reported a sale of 6,001 shares of common stock on August 11, 2026 at a weighted average price of $99.90 per share, in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2026. Following this transaction, Bjerkholt beneficially owns 36,355 shares of Mirum common stock, including 175 shares acquired on May 10, 2026 under the Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 6,001 shares

Net Sell 1 txn

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 6,001 shs ($600K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	6,001	$99.9016	$600K

Holdings After Transaction: Common Stock — 36,355 shares (Direct)

Footnotes (3)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.
2. F2. . The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.

Key Figures

Shares sold: 6,001 shares Weighted average sale price: $99.901633 per share Price range: $99.90–$99.93 per share +3 more

6 metrics

Shares sold 6,001 shares Common stock sold by CFO on August 11, 2026

Weighted average sale price $99.901633 per share Weighted average price for the reported sale transaction

Price range $99.90–$99.93 per share Range of prices for shares sold in the transaction

Shares owned after transaction 36,355 shares Total beneficial ownership of CFO following the sale

ESPP shares included 175 shares Shares acquired May 10, 2026 under Employee Stock Purchase Plan

10b5-1 plan adoption date March 9, 2026 Date CFO adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 Plan, weighted average sale price, Employee Stock Purchase Plan

3 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $99.901633"

Employee Stock Purchase Plan financial

"acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mirum Pharmaceuticals (MIRM) report for its CFO?

Mirum Pharmaceuticals reported that its CFO, Eric Bjerkholt, sold 6,001 shares of common stock on August 11, 2026. The transaction was a sale in the open market or a private transaction and was executed under a pre-established Rule 10b5-1 trading plan.

At what price did the Mirum Pharmaceuticals (MIRM) CFO sell his shares?

The CFO’s sale had a weighted average price of $99.901633 per share, with trade prices ranging between $99.90 and $99.93. Full details of the number of shares sold at each price level are available upon request from the company, SEC staff, or shareholders.

How many Mirum Pharmaceuticals (MIRM) shares does the CFO hold after this sale?

After the reported sale, the CFO beneficially owns 36,355 shares of Mirum Pharmaceuticals common stock. This total includes 175 shares that he acquired on May 10, 2026 through the company’s Employee Stock Purchase Plan.

Was the Mirum Pharmaceuticals (MIRM) CFO’s share sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the CFO on March 9, 2026. Such plans allow pre-arranged trading of shares according to set instructions, independent of subsequent inside information.

How many Mirum Pharmaceuticals (MIRM) shares did the CFO sell in this Form 4?

The CFO sold 6,001 shares of common stock in this reported transaction. According to the filing’s transaction summary, this represents a net sell of 6,001 shares, with no purchases or derivative exercises reported in the same Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		S(1)		6,001	D	$99.9016(2)	36,355(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.

2. . The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.

	/s/ Judit Ryvkin, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)